Heparin

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

FDA approvals rise 49% in 2023; CRISPR’s gene editing therapy sees light of day

In 2022, when the US Food and Drug Administration (FDA) was reeling under the impact of the pandem

COVID-19: India restricts drug exports amid rising prices of essential bulk drugs; FDA announces first drug shortage

Now that it has been established that the novel coronavirus is going to globally impact the drug s

Mid-2017 Recap of FDA Warning Letters, Import Alerts & EU Non-Compliances

Last year, data integrity was a hot topic of discussion in the pharmaceutical industry. According t

FDA proposes delayed track and trace rollout; GSK forays into artificial intelligence-aided drug research

This week, Phispers brings you news on an apex court ruling in Canada that overhauls its patent law

Compliance Wrap: Heparin quality concerns re-emerge in China, more trouble at Sun Pharma & Wockhardt

PharmaCompass looks at recent compliance concerns highlighted by the US FDA at drug manufacturers li

If deleting electronic records is okay, then it must be okay to rip out pages from lab notebooks

This week, Speak Pharma interviews Mark S. Paxton, the Chief Executive Officer of Rx-360, a non-prof

Data integrity has no relationship with product quality

Peter J. Werth, President and Chief Executive Officer, ChemWerth, a US-headquartered full-service ge

Phispers: Another Heparin scandal in China, GSK may have a new CEO, Female libido pill problems

Pharmaceutical Whispers (Phispers) this week cover another major heparin scandal emanating from

Counterfeit drugs: Toyota’s highest ranking female employee arrested; it’s time to understand!

Yesterday, on July 1, 2015, the Drug Supply Chain Security Act (or Drug Quality and Security Act) b